Braveheart Bio, Inc.

BRVE

NASDAQHealthcareBiotechnology

在 GoAI 中打開

收盤時

US$27.45

+US$0.74 · +2.77%

9月16日下午4:00 ET

公司概況

公司網站

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Travis Murdoch
上市以來: 2026年8月6日
僱員: 49

市場位置

日內區間

目前US$27.45，

US$26.22US$28.90

52週區間

目前US$27.45，

US$24.31US$32.00

開盤價: US$26.82
前收盤價: US$26.71
成交量: 55.07萬; 1.25× 平均值
平均成交量: 44.06萬; 日均成交量
市值: 19.39億 USD
貝塔: 0; 市場參考 1
50天平均值: US$27.3482; 高於平均水平+0.37%
200天平均值: US$27.3482; 高於平均水平+0.37%

分析師評級

第三方分析師預期可能變動，並非 GoAI 建議。

分析師目標價

平均目標

US$45.25

上漲空間 64.85%

過去 12 個月12個月預測最高：US$48.00平均的：US$45.25最低：US$40.00

BRVE 訊息

globenewswire.com2026年9月16日

Braveheart Bio to Participate in Stifel Cardiometabolic Forum

SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other…

閱讀原始碼

globenewswire.com2026年9月8日

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart…

閱讀原始碼

globenewswire.com2026年9月1日

Braveheart Bio to Participate in Cantor Global Healthcare Conference

SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other…

閱讀原始碼

fool.com2026年8月10日

Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?

The transaction involved 27,777 shares acquired for ~$500,000 on August 7, 2026. The acquisition increased the total equity position by 5%, resulting in a 0.87% ownership stake.

閱讀原始碼

fool.com2026年8月10日

Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?

The transaction involved 83,333 shares with an estimated value of ~$1.5 million as of the August 7, 2026 market close. Director Viehbacher increased his direct equity holdings by 16% through this acquisition.

閱讀原始碼

fool.com2026年8月10日

Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?

Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake.

閱讀原始碼